An update on the management of latent tuberculosis infection and active disease in patients with chronic kidney disease

被引:8
|
作者
Myall, Katherine [1 ]
Milburn, Heather J. [1 ,2 ]
机构
[1] Guys & St Thomas NHS Fdn Trust, Dept Resp Med, London, England
[2] Kings Coll London, London, England
来源
POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ | 2017年 / 127卷 / 10期
关键词
chronic kidney disease; latent infection; tuberculosis; MYCOBACTERIUM-TUBERCULOSIS; ISONIAZID CHEMOPROPHYLAXIS; TRANSPLANT RECIPIENTS; ADULT PATIENTS; RIFABUTIN; NEUTROPENIA; RIFAMPIN; IMPACT; ASSAY; RISK;
D O I
10.20452/pamw.4093
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In 2010, the British Thoracic Society published guidelines on the management of tuberculosis (TB) infection and disease in patients with chronic kidney disease (CKD), in response to physicians' concerns about the challenges encountered in treating this complex patient group. Later, in 2010, we summarized the main messages from these guidelines for readers of this journal. The purpose of this review is an update on the current management of latent and active Mycobacterium tuberculosis infection in patients with CKD. Patients with CKD have an increased risk of both infection and disease with Mycobacterium tuberculosis, and practice varies between renal units. Since 2010, the majority of published data have focused on screening for TB infection in immunosuppressed patients, including those with CKD and transplant recipients. While there is currently no perfect screening test, the evidence suggests that we should be using the available interferon-gamma release assays, with or without the tuberculin skin test, to try and reduce the undoubted risk of active TB in these patients. While we are not aware of any new evidence to change the recommended treatment regimens, we have reiterated some of the important recommendations outlined in the original guidelines.
引用
收藏
页码:681 / 686
页数:6
相关论文
共 50 条
  • [21] Mycobacterium tuberculosis: Active disease and latent infection in a renal transplant cohort
    Rafiei, Nastaran
    Williams, Jackie
    Mulley, William R.
    Trauer, James M.
    Jenkin, Grant A.
    Rogers, Benjamin A.
    NEPHROLOGY, 2019, 24 (05) : 569 - 574
  • [22] Type 2 diabetes mellitus management in patients with chronic kidney disease: an update
    Zoi Kleinaki
    Stella Kapnisi
    Sofia-Andriani Theodorelou-Charitou
    Ilias P. Nikas
    Stavroula A. Paschou
    Hormones, 2020, 19 : 467 - 476
  • [23] Type 2 diabetes mellitus management in patients with chronic kidney disease: an update
    Kleinaki, Zoi
    Kapnisi, Stella
    Theodorelou-Charitou, Sofia-Andriani
    Nikas, Ilias P.
    Paschou, Stavroula A.
    HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2020, 19 (04): : 467 - 476
  • [24] Management of HCV infection in chronic kidney disease
    Aoufi Rabih, S.
    Garcia Agudo, R.
    NEFROLOGIA, 2011, 31 (03): : 260 - 267
  • [25] Management of patients with chronic kidney disease
    Schena, Francesco P.
    INTERNAL AND EMERGENCY MEDICINE, 2011, 6 : 77 - 83
  • [26] Diagnosis of Cardiovascular Disease in Patients with Chronic Kidney Disease
    McCullough, Peter A.
    Assad, Hadeel
    BLOOD PURIFICATION, 2012, 33 (1-3) : 112 - 118
  • [27] Coronary Artery Disease in Patients with Chronic Kidney Disease: A Clinical Update
    Cai, Qiangjun
    Mukku, Venkata K.
    Ahmad, Masood
    CURRENT CARDIOLOGY REVIEWS, 2013, 9 (04) : 331 - 339
  • [28] Management of patients with chronic kidney disease
    Francesco P. Schena
    Internal and Emergency Medicine, 2011, 6
  • [29] Management of patients with chronic kidney disease
    Gerntholtz, T.
    Paget, G.
    Hsu, P.
    Meyers, A. M.
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2015, 105 (03): : 237
  • [30] DOAC use in patients with chronic kidney disease An update
    Kuecuekkoeylue, Seher
    Rump, Lars Christian
    HAMOSTASEOLOGIE, 2017, 37 (04): : 286 - 294